Home > Inhibitors & Agonists > Tyrosine Kinase > EGFR
Cat. No. Product name CAS No.
DC11916 FD-5180

A novel protein kinase affinity probe...

2098621-92-0
DC11721 PF-06747775

A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.

1776112-90-3
DC5113 AEE-788 (NVP-AEE788) Featured

AEE788 is a potent inhibitor of EGFR and HER2/ErbB2 with IC50 of 2 nM and 6 nM, less potent to VEGFR2/KDR, c-Abl, c-Src, and Flt-1, does not inhibit Ins-R, IGF-1R, PKCα and CDK1. Phase 1/2.

497839-62-0
DC3164 BIBW2992-MA2 (Afatinib dimaleate) Featured

Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

850140-73-7
DC10589 AG 1406 Featured

AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2 .

71308-34-4
DC8079 AG-1557 Featured

AG-1557 is an ultra-potent inhibitor of epidermal growth factor receptor tyrosine kinase (EGFRK).

189290-58-2
DC1080 Tyrphostin 9(AG-17) Featured

AG-17 is an inhibitor of epidermal growth factor (EGF) receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.

10537-47-0
DC12382 AG-99 Featured

AG-99 is an inhibitor of EGF receptor kinase with an IC50 value of 10 µM in the human epidermoid carcinoma cell line A431.

122520-85-8
DC12072 Alflutinib (AST2818 mesylate) Featured

Alflutinib (AST-2818, ASK120067) is a third generation EGFR mutation selective tyrosine kinase inhibitor, inhibits EGFR active mutations as well as T790M acquired resistant mutation..

2130958-55-1
DC11495 Allitinib

Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays.

897383-62-9
DC10371 Anlotinib Featured

Anlotinib is a EGFR inhibitor extracted from patent 2015185012 A1, compound 1,which can be used to treat non-small cell lung cancer.

1058156-90-3
DC8486 Varlitinib(ARRY-334543)

ARRY-334543 is a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases.

845272-21-1
DC7360 AST-1306

AST-1306 is a novel irreversible inhibitor of EGFR and ErbB2 with IC50 of 0.5 nM and 3 nM, also effective in mutation EGFR T790M/L858R, more potent to ErbB2-overexpressing cells, 3000-fold selective for ErbB family than other kinases.

1050500-29-2
DC8253 AV-412(MP-412)

AV-412(MP-412) is a potent dual inhibitor of EGFR and ErbB2(IC50=19 nM) tyrosine kinases, including the mutant EGFR(L858R IC50=0.51 nM, T790M IC50=0.79 nM); inhibits autophosphorylation of EGFR and ErbB2 with IC(50) of 43 and 282 nM, respectively.

451492-95-8
DC10009 Avitinib free base Featured

Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity.

1557267-42-1
DC10008 Avitinib maleate Featured

Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity.

1557268-88-8
DC8052 AZ5104 Featured

AZ5104 is an active circulating metabolite of AZD9291.

1421373-98-9
DC8472 AZD-3759 Featured

AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity.

1626387-80-1
DC7006 Mereletinib(AZD-9291,Osimertinib) Featured

AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM).

1421373-65-0
DC8462 AZD-9291 mesylate (Osimertinib,Mereletinib) Featured

AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM).

1421373-66-1
DC3105 BMS-599626 (AC480) Featured

BMS-599626 (AC480) is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, respectively.

714971-09-2
DC3138 Canertinib dihydrochloride Featured

Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities.

289499-45-2
Page 1 / Total 4 FirstPrevNextLastGoto